Archives: Agenda

Compared to traditional pharmaceutical companies, the development and advancement of clinical pipelines employ significantly different strategies and methodologies. In response to the international R&D and clinical environment, targeted clinical development planning is required, with distinct operational priorities and practices.

• Artificial Intelligence Accelerates Global Drug Development Planning.
• Global Clinical Trial Strategy and
• Best Practices for Efficient Global Drug
• Packaging Strategies and Protocols for Clinical

英矽智能是全球领先的 AI 驱动生物科技公司，专注于 利用人工智能技术加速药物研发。和传统药企相比，临 床管线的开发和推进有着非常不同的策略和方法。针对 国际化的研发和临床环境，需要针对性的临床研发布 局，在运作层面也有不同的重点和实践

• 人工智能加速全球药物研发布局
• 全球临床试验策略和布局
• 全球高效药品供应的最佳实践
• 针对临床方案的包装策略和方案

Outsourcing and supply chains are being reshaped by global disruption and changes in the drug industry. Join Fiona Barry for an interactive deep dive into clinical trial supply trends, risks, and innovations.

• The latest global trends in clinical trial supply and
• How geopolitical shifts are reshaping supply chain
• Practical approaches for tackling drug shortages and managing risk.
• Insights from a survey of industry leaders in APAC, North America, and Europe

• 临床试验供应与外包的最新全球趋势
• 地缘政治变化如何重塑供应链战略
• 应对药品短缺与管理风险的实用策略
• 来自亚太、北美及欧洲行业领袖的调研洞见

• Interpretation of Policies on Cross-Border Data Transfer in the Pharmaceutical Industry
• Analysis of the Negative List Policy in the Pharmaceutical Industry
• Sharing Compliance Practices for Cross-Border Data Transfer in the Pharmaceutical Industry

• 医药行业数据出境政策解读
• 医药行业负面清单政策解读
• 医药行业数据出境合规实践分享

• Challenges in Clinical Drug Supply
• Application of New Technologies in Clinical Drug Supply Management.
• Global Case Studies and

• 临床药物供应管理的挑战
• 临床药物供应管理的新技术应用
• 全球案例分享与探讨。

• Updates on China’s National Medical Products Administration (NMPA)
• Recent reforms in drug and device approval
• Best practices for obtaining IND and NDA approvals in China

• 中国国家药品监督管理局（NMPA）法规更新
• 药品和医疗器械审批流程的最新改革
• 在中国获得 IND（新药临床试验申请）和 NDA（新药上市申请）批准的最佳实践